Clin2
NCT06704516Possibly a fitRecruiting

HRT and fatty liver disease in menopausal women – a pilot study

MenopauseMetabolic Dysfunction Associated Steatotic Liver Disease

Treatments studied

Part of Digestive system clinical trials.

This study tests whether starting hormone replacement therapy (HRT) improves liver health in women with menopause and fatty liver disease (MASLD). It aims to understand how HRT might help reduce fat in the liver.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
10 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are a woman aged 18 or older
  • You have gone through menopause (no periods for at least a year, or had your ovaries removed)
  • You have fatty liver disease (MASLD) but no other liver disease
  • You have not used hormone replacement therapy (HRT) in the last 3 months
  • You weigh between BMI 18 and 45 – this covers most body sizes
  • You are willing to have an MRI scan and receive information about the trial

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07386665Not yet recruiting
Exercise timing for liver health in postmenopausal women

This study tests whether the time of day you exercise affects liver fat and overall health in postmenopausal women with fatty liver disease. It may help you find a simple way to improve your liver health without medication.

Almería
NCT07877272Recruiting
Better liver testing for high-risk fatty liver disease

This study tests a more detailed way to examine the liver in people with fatty liver disease who also have other health risks. The doctors want to see if this extra testing helps decide whether you need treatment.

Münster
NCT07165028Recruiting· Phase 3
Study of new drugs for fatty liver with scarring

This trial tests new medicines for adults with fatty liver disease (MASLD) that has already caused some liver scarring. It aims to see if these drugs can help prevent the liver disease from getting worse.

Tuscaloosa, Alabama
NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease

This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.

London, London
NCT06891365Recruiting· Phase 1
Multiple doses of a new drug for fatty liver disease

This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.

Harrow
NCT07193927Recruiting· Phase 2
Testing a probiotic mix for fatty liver disease (MASLD)

This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.

Girona, Girona

Hear when a new Menopause trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.